T
Thomas N. Martin
Researcher at University of Glasgow
Publications - 29
Citations - 1315
Thomas N. Martin is an academic researcher from University of Glasgow. The author has contributed to research in topics: Myocardial infarction & Cardiac magnetic resonance imaging. The author has an hindex of 14, co-authored 29 publications receiving 1235 citations. Previous affiliations of Thomas N. Martin include University of Dundee & Western Infirmary.
Papers
More filters
Journal ArticleDOI
Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.
Patrick B. Mark,Patrick B. Mark,Nicola Johnston,B. A. Groenning,John E. Foster,Kevin G. Blyth,Thomas N. Martin,Tracey Steedman,HJ Dargie,Alan G. Jardine,Alan G. Jardine +10 more
TL;DR: It is shown that LVH is the predominant cardiomyopathy specific to uremia, while LV dilation and systolic dysfunction are due to underlying (possibly silent) ischemic heart disease.
Journal ArticleDOI
Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension
Kevin G. Blyth,Bjoern A. Groenning,Thomas N. Martin,John E. Foster,Patrick B. Mark,Henry J. Dargie,Andrew J. Peacock +6 more
TL;DR: DCE was present within the RVIPs and IVS of most patients with PHT and may provide a novel marker for occult septal abnormalities directly relating to the haemodynamic stress experienced by these patients.
Journal Article
Redefinition of uremic cardiomyopathy by contrast- enhanced cardiac magnetic resonance imaging. Authors' reply
J. Aoki,K. Hara,Patrick B. Mark,Nicola Johnston,B. A. Groenning,John E. Foster,Kevin G. Blyth,Thomas N. Martin,Tracey Steedman,H. J. Dargie,Alan G. Jardine +10 more
TL;DR: In this paper, the authors studied the relationship between left ventricular (LV) function and myocardial pathology in end stage renal failure patients with CMR and showed that myocardious fibrosis was associated with the presence of left ventric hypertrophy.
Journal ArticleDOI
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study
Gilles Montalescot,Bertram Pitt,Esteban López de Sá,Christian W. Hamm,Marcus Flather,Freek W.A. Verheugt,Harry Shi,Eva Turgonyi,Miguel Orri,John Vincent,Faiez Zannad,Georg Noll,Robin A.P. Weir,Blair J. O'Neill,Michael Böhm,W. Stuart Hillis,Andrew Grieve,Jean-Lucien Rouleau,Filippatos Gerasimos,David Fitchett,Serge Lepage,Minakshi Madan,Bruce Sussex,Gerald Tremblay,Robert C. Welsh,Graham C. Wong,Martin Hutyra,Jiri Kettner,Petr Ostadal,Jindrich Spinar,Jan Vojacek,Michel Barboteu,Jean-Philippe Collet,Pierre Coste,Yves Cottin,Dominique Ducos,Michel Galinier,Emmanuel Teiger,Gilles Zemour,Johann Bauersachs,Rainer Hambrecht,Gerhard Hauf,Hubertus Heuer,Harald Mudra,Thomas Münzel,Stephan Steiner,Ruth H. Strasser,Karsten Sydow,Carsten Tschöpe,Rolf Wachter,Nikos Werner,Dimitros Alexopoulos,Dimitrios Babalis,Vlassios N Pyrgakis,Csaba András Dézsi,Geza Lupkovics,Peter Polgar,János Tomcsányi,J. Herrman,J. M. Ten Berg,Jerzy Gorny,Jacek Kubica,Jerzy Lewczuk,Witold Zmuda,Marian Hranai,Frantisek Kovar,Roman Margoczy,Karol Micko,Jaroslav Sumbal,Xavier Bosch Genover,Antonio Fernández Ortiz,Miguel Fiol Sala,Cosme Garcia Garcia,Carlos Perez Muñoz,Juan Ramon Rey Blas,Franciso Ridocci Soriano,Dawn L. Adamson,Farqad Alamgir,Anoop Chauhan,Gregory Y.H. Lip,Thomas N. Martin,Gerry P McCann,David E. Newby,David Smith +83 more
TL;DR: The addition of eplerenone during the acute phase of STEMI was safe and well tolerated and reduced the primary endpoint over a mean 13 months follow-up mostly because of significantly lower BNP/NT-proBNP levels.
Journal ArticleDOI
NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension
Kevin G. Blyth,Bjoern A. Groenning,Patrick B. Mark,Thomas N. Martin,John E. Foster,Tracey Steedman,J. J. Morton,HJ Dargie,Andrew J. Peacock +8 more
TL;DR: N-terminal B-type natriuretic peptide could prove useful as an objective, noninvasive means of identifying patients with pulmonary hypertension who have right ventricular systolic dysfunction at presentation.